Los Angeles Capital Management LLC Has $1.87 Million Stock Position in Collegium Pharmaceutical, Inc. $COLL

Los Angeles Capital Management LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 39.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,441 shares of the specialty pharmaceutical company’s stock after selling 26,799 shares during the quarter. Los Angeles Capital Management LLC owned 0.13% of Collegium Pharmaceutical worth $1,872,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in Collegium Pharmaceutical in the 4th quarter worth $5,209,000. Hillsdale Investment Management Inc. lifted its stake in shares of Collegium Pharmaceutical by 1.8% in the fourth quarter. Hillsdale Investment Management Inc. now owns 206,600 shares of the specialty pharmaceutical company’s stock valued at $9,566,000 after buying an additional 3,600 shares during the period. Intech Investment Management LLC lifted its stake in shares of Collegium Pharmaceutical by 25.5% in the fourth quarter. Intech Investment Management LLC now owns 108,855 shares of the specialty pharmaceutical company’s stock valued at $5,040,000 after buying an additional 22,146 shares during the period. Jackson Creek Investment Advisors LLC grew its position in Collegium Pharmaceutical by 263.9% during the fourth quarter. Jackson Creek Investment Advisors LLC now owns 38,846 shares of the specialty pharmaceutical company’s stock worth $1,799,000 after buying an additional 28,170 shares in the last quarter. Finally, AlphaQuest LLC grew its position in Collegium Pharmaceutical by 27.9% during the fourth quarter. AlphaQuest LLC now owns 31,967 shares of the specialty pharmaceutical company’s stock worth $1,480,000 after buying an additional 6,964 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Needham & Company LLC restated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. Finally, Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Stock Up 1.2%

Shares of COLL opened at $34.80 on Thursday. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company has a 50-day moving average price of $33.94 and a two-hundred day moving average price of $40.65. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of 17.06 and a beta of 0.74. Collegium Pharmaceutical, Inc. has a 12 month low of $29.08 and a 12 month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. During the same period in the prior year, the company posted $1.49 EPS. The company’s revenue was up 8.9% compared to the same quarter last year. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP David Dieter sold 13,976 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president directly owned 77,071 shares in the company, valued at $2,691,319.32. This represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.85% of the stock is owned by company insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.